NCT02826018View on ClinicalTrials.gov

A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection

PHASE1TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 24, 2016

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Hepatitis BChronic Hepatitis BHepatitis B, ChronicHepatitis B InfectionHBV
Interventions
DRUG

ALN-HBV

Ascending doses of ALN-HBV by subcutaneous (sc) injection

DRUG

Sterile Normal Saline (0.9% NaCl)

Calculated volume to match active comparator

Trial Locations (9)

Unknown

Clinical Trial Site, Adelaide

Clinical Trial Site, Fitzroy

Clinical Trial Site, Parkville

Clinical Trial Site, Hong Kong

Clinical Trial Site, Auckland

Clinical Trial Site, Singapore

Clinical Trial Site, London

03080

Clinical Trial Site, Seoul

05505

Clinical Trial Site, Seoul

Sponsors
All Listed Sponsors
lead

Alnylam Pharmaceuticals

INDUSTRY